RESMED, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 216 USD | +17.75% |
|
+19.31% | +24.05% |
| 05:37pm | KeyBanc Adjusts Price Target on ResMed to $238 From $227 | MT |
| 05:04pm | ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17% | MT |
Financials (USD)
| Sales 2024 * | 4.68B | Sales 2025 * | 5B | Capitalization | 26.94B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.02B | Net income 2025 * | 1.19B | EV / Sales 2024 * | 5.9 x |
| Net Debt 2024 * | 676M | Net cash position 2025 * | 262M | EV / Sales 2025 * | 5.34 x |
| P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
23.3
x | Employees | 10,140 |
| Yield 2024 * |
1.07% | Yield 2025 * |
1.16% | Free-Float | 77.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on ResMed, Inc.
More recommendations
More press releases
More news
| 1 day | +17.58% | ||
| 1 week | +19.03% | ||
| Current month | +7.50% | ||
| 1 month | +9.64% | ||
| 3 months | +11.96% | ||
| 6 months | +53.46% | ||
| Current year | +23.76% |
1 week
178.49
218.36
1 month
172.19218.36
Current year
164.12218.36
1 year
132.24243.52
3 years
132.24301.34
5 years
102.56301.34
10 years
45.74301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
Brett Sandercock
DFI | Director of Finance/CFO | 57 | 97-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Ron Taylor
BRD | Director/Board Member | 76 | 04-12-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 213.5 | +16.39% | 2 383 568 |
| 24-04-25 | 183.4 | -0.20% | 1,124,546 |
| 24-04-24 | 183.8 | -0.24% | 973,428 |
| 24-04-23 | 184.2 | +2.15% | 1,202,959 |
| 24-04-22 | 180.4 | +0.84% | 1,218,743 |
Delayed Quote Nyse, April 26, 2024 at 12:13 pm EDT
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
183.4
USD
Average target price
208.6
USD
Spread / Average Target
+13.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.76% | 26.94B | |
| +7.98% | 218B | |
| +6.81% | 182B | |
| +11.01% | 132B | |
| +26.26% | 108B | |
| +14.30% | 52.98B | |
| -0.62% | 47.59B | |
| -0.73% | 39.96B | |
| +10.98% | 39.22B | |
| -11.32% | 19.28B |
- Stock Market
- Equities
- RMD Stock
